Cargando…

Quality of life in ATTR amyloidosis

Detalles Bibliográficos
Autores principales:	Lane, Thirusha, Bangova, Alica, Fontana, Marianna, Hutt, David F, Strehina, Svetla G, Whelan, Carol J, Hawkins, Philip N, Gillmore, Julian D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Oral Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4642114/ http://dx.doi.org/10.1186/1750-1172-10-S1-O26

Ejemplares similares

Diflunisal therapy for cardiac ATTR amyloidosis: a longitudinal, prospective, single centre study
por: Quarta, Candida C, et al.
Publicado: (2015)

DPD Scintigraphy for diagnosis of amyloidosis in 1191 patients– a single centre experience
por: Hutt, David, et al.
Publicado: (2015)

Spotting senile systemic amyloidosis: why we miss it
por: Fontana, Marianna, et al.
Publicado: (2015)

Native T1 mapping in ATTR cardiac amyloidosis - comparison with AL cardiac amyloidosis - a 200 patient study
por: Fontana, Marianna, et al.
Publicado: (2014)

ATTR Amyloidosis: development of cardiac symptoms during 6 years of follow up in different ATTR-variants
por: Klaassen, Sebastiaan, et al.
Publicado: (2015)

LGE-PSIR is an independent predictor of mortality in cardiac amyloidosis: a 250 patient prospective study
por: Fontana, Marianna, et al.
Publicado: (2015)

Conventional heart failure therapy in cardiac ATTR amyloidosis
por: Ioannou, Adam, et al.
Publicado: (2023)

Patterns of late gadolinium enhancement in 94 patients with AL or transthyretin cardiac amyloidosis
por: Dungu, Jason, et al.
Publicado: (2012)

Empirical use of anakinra in AA amyloidosis of uncertain aetiology
por: Lane, T, et al.
Publicado: (2015)

Multi-modality imaging in cardiac ATTR amyloidosis: agreement between echocardiography, MRI and DPD-scintigraphy
por: Eliahou, Ludivine, et al.
Publicado: (2015)

Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy
por: Adams, David, et al.
Publicado: (2020)

Impact of Earlier Diagnosis in Cardiac ATTR Amyloidosis Over the Course of 20 Years
por: Ioannou, Adam, et al.
Publicado: (2022)

Guidelines for genetic counselling in ATTR amyloidosis
por: Sequeiros, Jorge
Publicado: (2015)

Heart transplantation in hereditary ATTR amyloidosis
por: Slama, M
Publicado: (2015)

Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis
por: Gillmore, Julian D, et al.
Publicado: (2015)

Occult senile cardiac amyloid in severe calcific aortic stenosis is not rare and has a poor prognosis: a 146 patient CMR biopsy study
por: Treibel, Thomas A, et al.
Publicado: (2016)

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2021)

Positron Emission Tomography (PET) utilizing Pittsburgh compound B (PIB) detects amyloid heart deposits in hereditary transthyretin amyloidosis (ATTR).
por: Pilebro, Björn, et al.
Publicado: (2015)

Multiorgan ECV as measured by EQ-MRI in systemic amyloidosis
por: Banypersad, Sanjay M, et al.
Publicado: (2013)

Imaging cardiac ATTR amyloid
por: Hawkins, Philip N
Publicado: (2015)

Disease progression in cardiac transthyretin amyloidosis is indicated by serial calculation of National Amyloidosis Centre transthyretin amyloidosis stage
por: Law, Steven, et al.
Publicado: (2020)

TUDCA as an autophagic modulator of ATTR V30M Amyloidosis
por: Teixeira, Cristina, et al.
Publicado: (2015)

The role of complement in ATTR amyloidosis: a new therapeutic avenue?
por: Panayiotou, Elena, et al.
Publicado: (2015)

Five novel TTR variants: associated phenotypes and structural consequences
por: Rowczenio, Dorota, et al.
Publicado: (2015)

Analysis of disease progression in patients with transthyretin cardiac amyloidosis
por: Gilmore, Julian D, et al.
Publicado: (2015)

The landscape of treatment of chronic kidney disease in hereditary ATTR amyloidosis
por: Lobato, Luisa
Publicado: (2015)

Symptomatic therapy in ATTR amyloidosis: pain killers in TTR-FAP
por: Attal, Nadine
Publicado: (2015)

Cardiac amyloid burden assessment by T1 mapping predicts survival in patients with systemic AL amyloidosis - a 2 year follow-up study
por: Banypersad, Sanjay M, et al.
Publicado: (2014)

Clinical and Genetic Evaluation of People with or at Risk of Hereditary ATTR Amyloidosis: An Expert Opinion and Consensus on Best Practice in Ireland and the UK
por: Gillmore, Julian D., et al.
Publicado: (2022)

Patients with hereditary ATTR amyloidosis experience an increasing burden of illness as the disease progresses
por: Adams, David, et al.
Publicado: (2015)

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
por: Brito, Dulce, et al.
Publicado: (2023)

Transthyretin cardiac amyloidosis
por: Porcari, Aldostefano, et al.
Publicado: (2022)

Do we need to demonstrate amyloid in tissue for hereditary ATTR amyloidosis ?
por: Westermark, Per
Publicado: (2015)

Diagnosis and Treatment of AL and ATTR Amyloidosis
por: Faiman, Beth, et al.
Publicado: (2021)

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
por: Judge, Daniel P., et al.
Publicado: (2020)

AL and ATTR cardiac amyloid are different: native T1 mapping and ECV detect different biology
por: Fontana , Marianna, et al.
Publicado: (2014)

Consensus recommendations on holistic care in hereditary ATTR amyloidosis: an international Delphi survey of patient advocates and multidisciplinary healthcare professionals
por: Obici, Laura, et al.
Publicado: (2023)

Diagnostic value of fat aspirates for amyloidosis in 950 patients
por: Gilbertson, JA, et al.
Publicado: (2015)

ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable
por: Brannagan, Thomas H., et al.
Publicado: (2021)

Unravelling the epidemiology of late-onset and asymptomatic carriers of FAP ATTR V30M in a Portuguese population
por: Lemos, Carolina, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_idkrfetj7cuumo3fevibfd0gj7